Investigational drug · Phase 2
LY3938577
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diabetes Mellitus, Type 2.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "LY3938577"
First trial start
2025
Oct 13, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LY3938577", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetes Mellitus, Type 2
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "LY3938577" as an intervention, largest first.
- A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT06280703 · 121 participants · Start May 15, 2024 · Primary completion Oct 3, 2026
Drug: LY3938577; Placebo and 7 more · For: Healthy; Type 1 Diabetes Mellitus
Sites: Neuss, Germany
- A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal InsulinPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07215312 · 100 participants (planned) · Start Oct 13, 2025 · Primary completion Nov 2026
Drug: LY3938577; Degludec · For: Diabetes Mellitus, Type 2
Sites: Tucson, Arizona; Spring Valley, California; Tustin, California · 26 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT06132126 · 66 participants · Start Nov 17, 2023 · Primary completion Jun 28, 2024
Drug: LY3938577; Placebo and 1 more · For: Healthy; Type 2 Diabetes Mellitus
Sites: Anaheim, California; Miami, Florida; Dallas, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Diabetes Mellitus, Type 2
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.